Stock Research for ACST

ACST

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ACST Stock Chart & Research Data

The ACST chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACST chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ACST Due diligence Resources & Stock Charts

The ACST stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ACST Detailed Price Forecast - CNN Money CNN View ACST Detailed Summary - Google Finance
Yahoo View ACST Detailed Summary - Yahoo! Finance Zacks View ACST Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ACST Trends & Analysis - Trade-Ideas Barrons View ACST Major Holders - Barrons
NASDAQ View ACST Call Transcripts - NASDAQ Seeking View ACST Breaking News & Analysis - Seeking Alpha
Spotlight View ACST Annual Report - CompanySpotlight.com OTC Report View ACST OTC Short Report - OTCShortReport.com
TradeKing View ACST Fundamentals - TradeKing Charts View ACST SEC Filings - Bar Chart
WSJ View Historical Prices for ACST - The WSJ Morningstar View Performance/Total Return for ACST - Morningstar
MarketWatch View the Analyst Estimates for ACST - MarketWatch CNBC View the Earnings History for ACST - CNBC
StockMarketWatch View the ACST Earnings - StockMarketWatch MacroAxis View ACST Buy or Sell Recommendations - MacroAxis
Bullish View the ACST Bullish Patterns - American Bulls Short Pains View ACST Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ACST Stock Mentions - StockTwits PennyStocks View ACST Stock Mentions - PennyStockTweets
Twitter View ACST Stock Mentions - Twitter Invest Hub View ACST Investment Forum News - Investor Hub
Yahoo View ACST Stock Mentions - Yahoo! Message Board Seeking Alpha View ACST Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ACST - SECform4.com Insider Cow View Insider Transactions for ACST - Insider Cow
CNBC View ACST Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ACST - OTC Markets
Yahoo View Insider Transactions for ACST - Yahoo! Finance NASDAQ View Institutional Holdings for ACST - NASDAQ


Stock Charts

FinViz View ACST Stock Insight & Charts - FinViz.com StockCharts View ACST Investment Charts - StockCharts.com
BarChart View ACST Stock Overview & Charts - BarChart Trading View View ACST User Generated Charts - Trading View




Latest Financial News for ACST


Acasti Pharma Awarded Notice of Allowance for a Second Patent in China Covering CaPre’s Omega-3 Phospholipid Composition
Posted on Monday June 24, 2019

LAVAL, Québec, June 24, 2019 -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research,.


Acasti Pharma Announces TRILOGY 2 Trial Has Achieved its 100% Patient Randomization Target in Patients with Severe Hypertriglyceridemia
Posted on Tuesday June 04, 2019

Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that the Company’s TRILOGY 2 trial studying CaPre in patients with severe hypertriglyceridemia has achieved 100% patient randomization.  This follows the Company’s prior announcement in April 2019 that the Company’s TRILOGY 1 trial had achieved 100% patient randomization.


Acasti Issues Shares in Settlement of Claims with Former Chief Executive Officer
Posted on Thursday May 23, 2019

LAVAL, Québec, May 23, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has completed the previously disclosed issuance of 900,000 common shares from treasury to its former chief executive officer (the “Former CEO”) pursuant to the terms of a settlement agreement announced by the Company on May 10, 2019. Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk.


Acasti Pharma to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
Posted on Tuesday May 21, 2019

LAVAL, Québec, May 21, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it will be presenting at the 20th Annual B. Riley FBR Institutional Investor Conference on Wednesday, May 22nd, at 9:00 AM, PST. The conference is being held May 22-23, 2019 at The Beverly Hilton in Beverly Hills, California. Jan D’Alvise, Chief Executive Officer of Acasti, will be presenting a company overview as well as meeting with investors.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.